LPCN (Lipocine) Interest Expense : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Lipocine Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Lipocine's interest expense for the three months ended in Sep. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Lipocine's Operating Income for the three months ended in Sep. 2024 was $ -2.63 Mil. Lipocine's Interest Expense for the three months ended in Sep. 2024 was $ 0.00 Mil. Lipocine has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Lipocine Interest Expense Historical Data

The historical data trend for Lipocine's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipocine Interest Expense Chart

Lipocine Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.77

-0.39

-0.20

-0.03

Lipocine Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Lipocine Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Lipocine (NAS:LPCN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lipocine's Interest Expense for the three months ended in Sep. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2024 was $-2.63 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was $0.00 Mil.

Lipocine's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Lipocine had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Lipocine Inc has no debt.

Lipocine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipocine Inc (NAS:LPCN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108

Website

https://www.lipocine.com

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.

Executives

Mahesh V. Patel	director, officer: President and CEO	C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Richard Dana Ono	director	18 SPRING ROAD, CONCORD MA 01742
Spyridon Papapetropoulos	director	C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
George Nomikos	officer: Chief Medical Officer	675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Krista Fogarty	officer: Principal Accounting Officer	675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Jill M. Jene	director	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
John W. Higuchi	director	C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Morgan R Brown	officer: EVP and CFO	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Stephen A Hill	director	50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Jeffrey Arvin Fink	director	2265 MORNING STAR DRIVE, PARK CITY UT 84060
Gregory Brooks Bass	officer: EVP and Chief Commercial Offic	3228 BROOKSIDE DRIVE, FURLONG PA 18925
Jyrki Mattila	officer: Chief Business Officer	AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Srinivasan Venkateshwaran	officer: CTO and VP RandD	C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Robert K. Merrell	officer: VP Finance	C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Gerald T Simmons	officer: VP Corp Business Development	837 4TH AVE, SALT LAKE CITY UT 84103